Trial Profile
Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Domatinostat (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms EMERGE
- 02 Jul 2022 Results (n=21) reporting safety and efficacy data from oesophagogastric and colorectal adenocarcinoma cohorts presented at the 24th World Congress on Gastrointestinal Cancer
- 01 Feb 2022 Status changed from recruiting to discontinued, according to a 4SC media release.
- 01 Feb 2022 According to a 4SC AG media release, the company has decided to discontinue development of domatinostat because clinical information now available, and which will be published in due course, indicates that domatinostat is unlikely to provide value to patients, physicians, or shareholders.